Company
Spectranetics
Last checked: Nov 19, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
17
510(k), De Novo and PMA
Device trials
18
As lead sponsor, any status
Adverse event reports
586
Received Nov 1, 2025 to Nov 19, 2026
Recall records
21
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
From SEC filings.
We found no SEC financing filings under the name Spectranetics, so its financing is unknown here. That is common for companies based outside the US, for subsidiaries of larger companies, and for companies funded by founders, grants or customers. A company that changed its name can also be missed.
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
Latest FDA decisions
The 8 newest of 17 since 2015.
K250385 · Decided Mar 13, 2025 · 30 days after receipt
Device type: Catheter, Peripheral, Atherectomy (MCW) · Cardiology
K223472 · Decided Dec 15, 2022 · 28 days after receipt
Device type: Dilator, Vessel, For Percutaneous Catheterization (DRE) · Cardiology
- Turbo-Power (2.0mm) Laser Atherectomy Catheters, Turbo-Power (2.3mm) Laser Atherectomy Catheters510(k)
K222837 · Decided Dec 8, 2022 · 79 days after receipt
Device type: Catheter, Peripheral, Atherectomy (MCW) · Cardiology
14 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- Stellarex Vascular E-RegistryCompleted
NCT02769273 · 1,900 participants · Start Jun 2016 · Primary completion Oct 31, 2021
Device: Percutaneous Transluminal Angioplasty · For: Peripheral Arterial Disease
Sites: Graz, Austria; Ried im Innkreis, Austria; Vienna, Austria · 46 sites in all
NCT05361967 · 6 participants · Start Mar 30, 2023 · Primary completion Jun 1, 2024
Device: The Tack Endovascular System · For: PAD - Peripheral Arterial Disease; PAD; Dissection and 3 more
Sites: Thornton, Colorado; Hartford, Connecticut; Fort Lauderdale, Florida · 10 sites in all
- ILLUMENATE Pivotal Post-Approval Study (PAS)Pivotal-lookingCompleted
NCT03421561 · 300 participants · Start Jun 18, 2013 · Primary completion Dec 8, 2017
Device: Stellarex 0.035" OTW Drug-coated Angioplasty Balloon; EverCross™ 0.035 PTA Balloon Catheter · For: Peripheral Artery Disease
Sites: Yuma, Arizona; Fremont, California; Los Angeles, California · 41 sites in all
15 more trials with a free account
Reports received
586
Received Nov 1, 2025 to Nov 19, 2026. Includes 1 of another or unstated type.
Malfunction reports
99
17% of reports
Injury reports
370
63% of reports
Death reports
116
20% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 1 | 19 | 2 | 0 |
| Jan 24 | 5 | 17 | 1 | 0 |
| Feb 24 | 4 | 12 | 6 | 0 |
| Mar 24 | 9 | 12 | 3 | 0 |
| Apr 24 | 5 | 13 | 2 | 0 |
| May 24 | 10 | 21 | 5 | 0 |
| Jun 24 | 3 | 21 | 0 | 0 |
| Jul 24 | 3 | 11 | 2 | 0 |
| Aug 24 | 4 | 19 | 3 | 0 |
| Sep 24 | 7 | 12 | 3 | 0 |
| Oct 24 | 6 | 12 | 2 | 0 |
| Nov 24 | 2 | 13 | 2 | 0 |
| Dec 24 | 8 | 10 | 4 | 0 |
| Jan 25 | 3 | 18 | 1 | 0 |
| Feb 25 | 7 | 13 | 1 | 0 |
| Mar 25 | 5 | 11 | 2 | 0 |
| Apr 25 | 9 | 21 | 4 | 0 |
| May 25 | 5 | 14 | 2 | 0 |
| Jun 25 | 8 | 5 | 2 | 0 |
| Jul 25 | 6 | 26 | 8 | 0 |
| Aug 25 | 3 | 4 | 1 | 0 |
| Sep 25 | 8 | 25 | 2 | 0 |
| Oct 25 | 8 | 25 | 4 | 0 |
| Nov 25 | 10 | 9 | 1 | 1 |
| Dec 25 | 3 | 16 | 4 | 0 |
| Jan 26 | 7 | 21 | 4 | 0 |
| Feb 26 | 10 | 24 | 5 | 0 |
| Mar 26 | 14 | 25 | 9 | 0 |
| Apr 26 | 8 | 47 | 13 | 0 |
| May 26 | 6 | 61 | 26 | 0 |
| Jun 26 | 8 | 102 | 31 | 0 |
| Jul 26 | 10 | 14 | 7 | 0 |
| Aug 26 | 11 | 15 | 2 | 0 |
| Sep 26 | 6 | 23 | 8 | 0 |
| Oct 26 | 6 | 13 | 6 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
6 more in this ranking with a free account
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
7 more in this ranking with a free account
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1070-2025 · Started Jan 10, 2025 · Posted by FDA Feb 14, 2025
Reason given: Use of Tack Endovascular system, designed to treat acute dissections of inner wall or lining of an artery by tacking damaged tissue to inner luminal surface, could result in problems with deployment and stability of device in vessel after deployment, which may cause failure to resolve dissection, migration of implant,...
Cause as FDA categorized it: Device Design · Device type: Scaffold, Dissection Repair (QCT)
Z-0680-2025 · Started Nov 25, 2024 · Posted by FDA Dec 16, 2024
Reason given: Due to complaints received for the marker band detaching from the distal tip of the catheter and remaining in the patient as laser catheter was retracted.
Cause as FDA categorized it: Device Design · Device type: Catheter, Peripheral, Atherectomy (MCW)
Z-0509-2024 · Started Nov 15, 2023 · Posted by FDA Dec 8, 2023
Reason given: Incorrect product labeling. Exterior product box label does not match internal pouch label.
Cause as FDA categorized it: Packaging process control · Device type: Catheter, Peripheral, Atherectomy (MCW)
18 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.